Drug Trial Radar · NCT07082686
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
75
Planned (sponsor's estimate)
Start
Aug 21, 2025
Primary completion
Dec 2027
Study completion Jul 2028
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, multi-center, open-label, phase 2 study to evaluate the efficacy and safety of ICP-248 in subjects with relapsed or refractory mantle cell lymphoma.
Conditions
- Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Interventions
ICP-248Drug
Eligible patients will receive ICP-248 orally as per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rate (ORR) according to Lugano 2014 assessed by the independent review committee (IRC)Time frame: 3 years
Locations
29 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China · Recruiting
Peking University Third Hospital
Beijing, Beijing Municipality, China · Recruiting
West China Hospital of Sichuan University
Chengdu, Chengdu, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, China · Recruiting
Fujian Medical University Union Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
The First Affiliated Hospital of University of South China
Hengyang, Hunan, China · Recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Qilu Hospital of Shandong University
Jinan, Shandong, China · Recruiting
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xian, Shanxi, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
The Second People's Hospital of Yibin
Yibin, Sichuan, China · Recruiting
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China · Recruiting
The Affiliated Cancer Hospital of Xinjiang Medical University
Xinjiang, Xinjiang, China · Recruiting
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.